iTeos Therapeutics, Inc. (ITOS)
Market Cap | 653.46M |
Revenue (ttm) | n/a |
Net Income (ttm) | -135.31M |
Shares Out | 36.12M |
EPS (ttm) | -3.78 |
PE Ratio | n/a |
Forward PE | 12.56 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 287,551 |
Open | 18.04 |
Previous Close | 18.05 |
Day's Range | 17.65 - 18.70 |
52-Week Range | 8.20 - 18.75 |
Beta | 1.27 |
Analysts | Strong Buy |
Price Target | 33.75 (+86.57%) |
Earnings Date | May 10, 2024 |
About ITOS
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ITOS stock is "Strong Buy." The 12-month stock price forecast is $33.75, which is an increase of 86.57% from the latest price.
News
iTeos Therapeutics to raise $120 million via registered direct offering
iTeos Therapeutics Inc (NASDAQ: ITOS) is up 30% today after announcing plans of a registered direct offering. iTeos Therapeutics stock pops on Q1 earnings The biotechnology company will sell a total ...
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201 - Clinically meaningful tumor reducti...
iTeos Therapeutics Announces $120 Million Registered Direct Offering
- Led by existing investors RA Capital Management and Boxer Capital - Purchase price of $17.50 represents a premium of approximately 44% to last close - Further strengthens balance sheet with pro form...
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Completed enrollment of third dose coho...
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, March 01, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development...
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC - Completed enrollment of monotherapy dose e...
Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data
Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%,...
iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates
– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination
iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
– Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens
iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
- 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupa...
iTeos to Present at Cowen 43rd Annual Health Care Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
iTeos to Present at SVB Securities Global Biopharma Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 07, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
iTeos Provides Business Updates and Clinical Development Plans for 2023
- 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant
iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 22, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates
– Initiated a randomized Phase 2 trial evaluating anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and GSK's anti-PD-1 Jemperli (dostarlimab) in first line, metastatic non-small cell lung cancer
iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update
- Began enrolling patients with head and neck squamous cell carcinoma in Phase 2 trial expansion evaluating anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A, and GSK's anti-PD-1 Jemperli (dostarlim...
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer
STRASBOURG, France & MONTREAL, Canada--(BUSINESS WIRE)--Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Re...
iTeos Reports First Quarter 2022 Financial Results and Provides Business Update
WATERTOWN, Mass. and GOSSELIES, Belgium, May 12, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
Innoskel Appoints Dr Michel Detheux as Chairman
Inno s kel Appoints Dr Michel Detheux as Chairman